AbbVie: Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study

Date : 15/01/2020 @ 01:37
Source : Dow Jones News
Stock : AbbVie Inc (ABBV)
Quote : 88.0  -1.26 (-1.41%) @ 11:59
AbbVie share price Chart
After Hours
Last Trade
Last $ 88.00 ◊ 0.00 (0.00%)

AbbVie: Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study

AbbVie (NYSE:ABBV)
Historical Stock Chart

1 Month : From Dec 2019 to Jan 2020

Click Here for more AbbVie Charts.

By Michael Dabaie

 

AbbVie Inc. (ABBV) said Skyrizi met the primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx in a head-to-head Phase 3 study in adults with moderate to severe plaque psoriasis.

Skyrizi showed significantly higher rates of skin clearance compared with Cosentyx, meeting the primary endpoint of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index at week 52, AbbVie said.

AbbVie shares were up 1% to $87.64 premarket trade Tuesday.

The safety profile of Skyrizi was consistent with that observed in previously reported studies, with no new safety signals observed through week 52, the company said.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

January 14, 2020 09:22 ET (14:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Your Recent History
FX
EURAUD
Euro vs Au..
FX
USDAUD
US Dollar ..
ASX
WPL
Woodside
NASDAQ
AAPL
Apple
ASX
BHP
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20200120 03:38:55